Mitchell Brigell
Chief Tech/Sci/R&D Officer at OCUPHIRE PHARMA, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Caley Castelein | M | 53 |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 7 years |
| Joseph H. Gardner | M | 68 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 13 years |
| Richard Rodgers | M | 57 | 4 years | |
| Cam Gallagher | M | 54 | 5 years | |
| Cheryl Cohen | F | 58 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 6 years |
| Bernhard Hoffmann | M | 68 | 6 years | |
| Amy Rabourn | F | 44 | 5 years | |
| Stephen Pakola | M | 55 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 9 years |
| George Magrath | M | 40 | 1 years | |
| Sean Ainsworth | M | 56 | 6 years | |
| Erik Sims | M | - | 3 years | |
| Susan Benton | F | 59 | 4 years | |
| James Manuso | M | 75 | 5 years | |
| Jay Pepose | M | 69 | 3 years | |
| Chris Kontos | M | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Dietmar Vestweber | M | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Barbara Withers | F | - | - | |
| Joseph Schachle | M | 59 | 1 years | |
| Ronil Patel | M | - | 3 years | |
| Drey Coleman | F | - | - | |
| Kevin G. Peters | M | 67 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Nirav Jhaveri | M | 46 | - | |
| Anupam Dalal | M | 52 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Ash Jayagopal | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Rogers | M | 64 | 2 years | |
| Regina Marek | F | 55 | 3 years | |
| Steven Prelack | M | 66 | 4 years | |
| Stephen Hoffman | M | 70 | 2 years | |
| Muneer Satter | M | 63 | 7 years | |
| Chau Khuong | M | 48 | - | |
| Dhaval Desai | M | - | 4 years | |
| Pravin Dugel | M | 60 | 4 years | |
| Paul Weiss | M | 66 | 7 years | |
| Ginger Gregory | M | 56 |
Novartis Institutes of Biomedical Research
 Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | 7 years |
| Joan Mannick | M | 66 |
Novartis Institutes of Biomedical Research
Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | 7 years |
| David Chao | M | 56 |
Novartis Institutes of Biomedical Research
Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 36 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mitchell Brigell
- Personal Network
